Our sites enrolled a very large number of patients for Lantheus. Katy Cardiology enrolled 55 patients and became the global highest enrolling site! There were over 100 sites involved, so this was an amazing accomplishment.
Read More
We had 22 patients enrolled between 3 sites, which we consolidated to 2 sites after the first year. Most patients participated for over 3 years in this endpoint-driven trial.
Read More
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Read More
With this long-term Atrial Fibrillation trial, 22 patients were enrolled at Katy Cardiology, most of whom remained in the trial for over 3 years to help Daaichi determine if Edoxaban was superior to Warfarin, among other things.
Read More
Most patients participated for almost 3 years, taking the study medication daily. The trial was designed to test if the study drug was effective in preventing heart attacks and strokes in patients with known coronary disease after a previous cardiovascular event.
Read More